{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:51:45Z","timestamp":1789480305493,"version":"build-2803163510"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Primary high-grade urothelial carcinoma of the prostate (PHUCP) combined with acinar adenocarcinoma is an extremely rare malignancy, with no previously reported cases worldwide. Primary urothelial carcinoma of the prostate (PUCP) accounts for only 1%-4% of all prostate malignancies, and its clinical manifestations often overlap with common prostatic diseases such as benign prostatic hyperplasia (BPH), leading to frequent misdiagnosis. This study presents the first documented case and summarizes the diagnostic and therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 61-year-old male patient presented with lower urinary tract symptoms and was initially diagnosed with BPH, later revised to Gleason score 10 prostate adenocarcinoma at external hospitals. Following an innovative port-free single-site robot-assisted radical prostatectomy (pf-ssRARP) at our institution, immunohistochemical analysis (CK7\/CK20\/GATA3 positive, prostate-specific antigen (PSA) negative) confirmed the diagnosis of PHUCP combined with acinar adenocarcinoma. Postoperatively, a surgery combined with targeted and immunotherapy regimen was initiated: leuprorelin + rezvilutamide for the acinar adenocarcinoma and disitamab vedotin + toripalimab for the urothelial carcinoma. No recurrence or metastasis was observed during the 1-year follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the diagnostic challenges of prostatic urothelial carcinoma and highlights the importance of immunohistochemistry in cases with normal PSA but rapid progression. The protocol of surgery combined with targeted and immunotherapy offers a new treatment strategy for this rare malignancy. This study provides valuable insights for clinical diagnosis and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1649636","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:29Z","timestamp":1761542369000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Primary high-grade urothelial carcinoma of the prostate combined with acinar adenocarcinoma: first rare case report and treatment experience summary"],"prefix":"10.3389","volume":"15","author":[{"given":"Ting","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpeng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangqing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"B1","article-title":"Prostate cancer epidemiology in 2022: A global perspective","volume":"30","author":"Smith","year":"2023","journal-title":"J Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.01.027","article-title":"Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance","volume":"37","author":"Shen","year":"2006","journal-title":"Hum Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/PAS.000000000000023","article-title":"Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S237099","article-title":"Biological and clinical significance of GATA3 detected from TCGA database and FFPE sample in bladder cancer patients","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"Gurel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31802f5d33","article-title":"Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma","volume":"31","author":"Chuang","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-005-0129-6","article-title":"Alpha-methylacyl-CoA racemase (AMACR\/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression","volume":"448","author":"Langner","year":"2006","journal-title":"Virchows Arch"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S162441","article-title":"Case report of a primary prostatic urothelial carcinoma patient with sustained fever","volume":"11","author":"Zhang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2023.2252102","article-title":"Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature","volume":"26","author":"Liu","year":"2023","journal-title":"Aging Male"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.011","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate","volume":"63","author":"Palou","year":"2013","journal-title":"Eur Urol"},{"key":"B12","article-title":"Primary urothelial carcinoma of the prostate: A case report and review of the literature","volume":"26","author":"Han","year":"2020","journal-title":"Zhonghua Nan Ke Xue"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume-title":"Lancet Oncol","author":"Gu","year":"2022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1649636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:29Z","timestamp":1761542369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1649636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":15,"alternative-id":["10.3389\/fonc.2025.1649636"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1649636","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"article-number":"1649636"}}